explore -WSS

explore

author：fashion 2025-10-01 14:20:33 - browse：52

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Argenx drug significantly slows progression of nerve disorder

explore

focus

WSS

Care demand spikes challenge UnitedHealth’s provider arm

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Congress: Eradicate hepatitis C and reduce the deficit

Europe sees delivery challenges ahead on Alzheimer's therapies

focus

explore

hotspot

Activists slam private health insurers over coverage restrictions

In utero gene editing: an explainer

Medicare proposal to cover medical devices draws a mixed reaction

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Europe sees delivery challenges ahead on Alzheimer's therapies

In Memoriam: Notable people who died in 2023

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

knowledge

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

6 phony surgeries that take placebo to the extreme

Congress likely to miss an opportunity to fix drug shortages issue

In utero gene editing: an explainer

explore

focus

focus

leisure time